Biocon Biologics Ltd (BBL), a leading biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), has announced a significant five-year partnership with Sandoz AG ('Sandoz') to exclusively promote, sell, and distribute biosimilar Trastuzumab and biosimilar Bevacizumab in Australia.

Under the terms of the agreement, Sandoz will have exclusive rights to distribute Biocon Biologics' renowned brands, OGIVRI® (bTrastuzumab) and ABEVMY® (bBevacizumab), ensuring continued access to these vital medications for patients in Australia. Trastuzumab, a biosimilar of Herceptin®, and Bevacizumab, a biosimilar of Avastin®, are both utilized in the treatment of various cancers and are available on the PBS (Pharmaceutical Benefits Scheme).

The partnership, effective from January 1, 2024, with commercialization initiated on February 1, 2024, signifies a crucial step in Biocon Biologics' global growth strategy. Matt Erick, Chief Commercial Officer of Advanced Markets at Biocon Biologics Ltd, emphasized the significance of this collaboration, stating, "This relationship underscores our commitment to ensuring patients in Australia have continued access to high-quality, affordable biosimilar medicines essential in oncology treatments."

This collaboration follows Biocon Biologics' recent strategic partnership with Sandoz in Japan, further solidifying its global presence and commitment to expanding access to critical treatments worldwide.